Enduring by Design: The Clinical and Economic Case for Chloroquine as a Cornerstone of Autoimmune Therapy in 2024

American medicine has a complicated relationship with novelty. The healthcare system pours billions into research and development, celebrates breakthrough designations, and markets innovation as synonymous with progress. Against this backdrop, the continued dominance of chloroquine—and its close structural relative hydroxychloroquine—in the management of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) invites a question worth examining carefully: Is this persistence a failure of imagination, or evidence of something more durable?

The answer, informed by decades of clinical data and the lived experience of rheumatologists across the country, is unambiguously the latter.

A Drug That Defies Its Own Age

Chloroquine entered clinical use as an antimalarial in the mid-twentieth century. Its immunomodulatory properties were recognized almost incidentally—physicians treating malaria patients with coexisting rheumatic conditions noted improvements in joint symptoms and skin manifestations. Subsequent decades of systematic investigation transformed that observation into a robust evidence base.

Today, the American College of Rheumatology recommends hydroxychloroquine—pharmacologically and clinically analogous to chloroquine for autoimmune purposes—as a baseline therapy for virtually all patients with SLE, barring specific contraindications. For rheumatoid arthritis, chloroquine-class drugs occupy a recognized position among conventional disease-modifying antirheumatic drugs (DMARDs). This is not a legacy designation preserved out of habit. It is a reflection of what the drug actually does, reliably and consistently, across a broad patient population.

The Mechanism Behind the Longevity

Understanding why chloroquine remains clinically indispensable requires a brief examination of its immunological mechanism. Unlike biologics that target discrete cytokines or cellular receptors, chloroquine operates through a more fundamental pathway: it accumulates in lysosomes and endosomes, raising their pH and thereby disrupting antigen processing, toll-like receptor signaling, and the downstream inflammatory cascades that drive autoimmune disease activity.

This broad, upstream mechanism of action produces several clinically significant effects. In lupus, it reduces flare frequency, lowers the risk of organ damage accrual, decreases thrombotic events, and—critically—has demonstrated a mortality benefit in long-term observational studies. In rheumatoid arthritis, it modulates systemic inflammation and, when used in combination regimens, contributes meaningfully to disease control.

Perhaps most importantly, chloroquine achieves these effects without the degree of immunosuppression associated with biologics. Patients do not face the same elevated risks of serious infection, opportunistic pathogens, or reactivation of latent tuberculosis that accompany many advanced therapies. For a condition like lupus—which disproportionately affects women of reproductive age and requires decades of ongoing management—this safety profile is not a minor consideration. It is often determinative.

The Economics of Irreplaceability

The financial dimension of this conversation cannot be separated from the clinical one, particularly in the American healthcare context.

Biologic therapies for autoimmune conditions carry annual costs that routinely exceed $20,000 to $50,000 per patient, with some agents approaching six figures when infusion costs and administration fees are included. Even with manufacturer assistance programs and insurance coverage, out-of-pocket burdens remain significant for many patients. Generic chloroquine and hydroxychloroquine, by contrast, are available for a fraction of that cost—often well under $500 annually at standard doses.

For healthcare systems managing large populations of lupus and RA patients, the cost differential is staggering. Medicaid programs, which cover a disproportionate share of lupus patients given the disease's demographic profile, have a particularly acute interest in preserving access to effective, affordable therapies. Formulary decisions that deprioritize older generics in favor of branded biologics have downstream consequences for both payer budgets and patient access.

Rheumatologists consulted in the preparation of this analysis consistently described cost as a genuine clinical variable—not a secondary consideration. When a patient faces a choice between a medication they can reliably afford and one requiring ongoing prior authorization battles, the practical calculus shifts regardless of theoretical efficacy differences.

Addressing the Patient Concern: Older Does Not Mean Inferior

One of the more persistent challenges rheumatologists face is counseling patients who arrive at their appointments having researched newer biologic options and wondering why they are being prescribed something their parents or grandparents might have taken. The concern is understandable in a cultural moment that equates technological recency with therapeutic superiority.

The clinical response to this concern rests on several pillars.

Safety data depth: Chloroquine has been administered to millions of patients over seven decades. Its side effect profile—most notably the risk of retinal toxicity with long-term use, which is manageable through established ophthalmologic monitoring protocols—is comprehensively characterized. Newer biologics, however promising, carry uncertainty that only time and post-market surveillance can resolve.

Comparative effectiveness: For mild-to-moderate lupus and as a component of RA combination therapy, chloroquine-class drugs perform comparably to far more expensive alternatives in controlled studies. The incremental benefit of biologic escalation is most clearly demonstrated in patients with inadequate response to conventional DMARDs—not as initial therapy.

Synergistic potential: Chloroquine is frequently used alongside methotrexate, hydroxychloroquine, or sulfasalazine in combination regimens. Its inclusion often allows lower doses of companion agents, reducing cumulative toxicity risk across the treatment program.

The Monitoring Imperative

No intellectually honest account of chloroquine's role in autoimmune therapy omits the retinal toxicity question. Cumulative doses exceeding established thresholds—particularly in patients with renal impairment or certain retinal risk factors—can cause maculopathy that, in advanced cases, may be irreversible. The 2016 American Academy of Ophthalmology guidelines established a risk-stratified monitoring framework that has substantially improved early detection and, consequently, reduced the incidence of clinically significant vision loss.

For patients and prescribers alike, the message is not that retinal risk is trivial—it is that it is manageable. Regular ophthalmologic screening, dose optimization relative to ideal body weight, and attention to cumulative exposure convert an absolute contraindication narrative into a monitored risk narrative. This distinction matters enormously for patients who might otherwise discontinue a medication that is controlling their disease effectively.

Looking Forward: Chloroquine's Place in an Evolving Landscape

The rheumatology landscape of 2024 is vastly more complex than it was when chloroquine first entered autoimmune practice. JAK inhibitors, IL-6 antagonists, B-cell depleting agents, and interferon pathway modulators have expanded the therapeutic toolkit considerably. For patients with severe or refractory disease, these advances represent genuine progress.

But the expansion of options does not diminish the value of foundational therapies that work. Chloroquine's endurance is not a placeholder waiting to be replaced—it is a benchmark that newer agents must demonstrate they can surpass in specific clinical contexts before displacing it. In the absence of that demonstration, for the broad population of lupus and RA patients managed across American rheumatology practices daily, chloroquine remains what the evidence says it is: a first-line therapy whose age is, ultimately, its credential.